Citigroup Inc Cyma Bay Therapeutics, Inc. Transaction History

Citigroup Inc

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 09, 2024	BUY	$12.63 - $24.47 $361,104 - $699,621	28,591 Added 155.27%	47,005 $1.11 Million
Q3 2023 Nov 09, 2023	SELL	$10.86 - $17.62 $327,787 - $531,824	-30,183 Reduced 62.11%	18,414 $274,000
Q2 2023 Aug 10, 2023	SELL	$7.47 - $10.95 $1.39 Million - $2.03 Million	-185,699 Reduced 79.26%	48,597 $532,000
Q1 2023 May 11, 2023	BUY	$5.88 - $9.59 $27,688 - $45,159	4,709 Added 2.05%	234,296 $2.04 Million
Q4 2022 Feb 09, 2023	BUY	$3.22 - $6.27 $381,582 - $743,020	118,504 Added 106.68%	229,587 $1.44 Million
Q3 2022 Nov 10, 2022	SELL	$2.77 - $4.25 $419,159 - $643,114	-151,321 Reduced 57.67%	111,083 $389,000
Q2 2022 Aug 10, 2022	BUY	$1.72 - $3.39 $441,857 - $870,870	256,894 Added 4662.32%	262,404 $774,000
Q1 2022 May 12, 2022	SELL	$2.77 - $3.64 $42,159 - $55,400	-15,220 Reduced 73.42%	5,510 $17,000
Q4 2021 Feb 10, 2022	BUY	$3.23 - $4.6 $28,120 - $40,047	8,706 Added 72.41%	20,730 $70,000
Q3 2021 Nov 10, 2021	BUY	$3.47 - $4.42 $41,723 - $53,146	12,024 New	12,024 $44,000

1.82M

Ticker CBAY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,677,904
Description
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of pri...

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

Stay updated on Citigroup Inc with notifications on news.